Published in J Natl Med Assoc on August 01, 2005
Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med (2009) 1.40
Osteoporosis, inflammation and ageing. Immun Ageing (2005) 1.40
T cell replicative senescence in human aging. Curr Pharm Des (2013) 1.31
Associations of cigarette smoking with rheumatoid arthritis in African Americans. Arthritis Rheum (2010) 1.09
Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Ann Rheum Dis (2008) 0.99
Reference ranges for bone mineral density and prevalence of osteoporosis in Vietnamese men and women. BMC Musculoskelet Disord (2011) 0.91
The anti-inflammatory role of vitamin e in prevention of osteoporosis. Adv Pharmacol Sci (2011) 0.89
Impact of interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans. Arthritis Rheum (2012) 0.87
Skeletal health among African Americans with recent-onset rheumatoid arthritis. Arthritis Rheum (2009) 0.83
Nigella sativa: A Potential Antiosteoporotic Agent. Evid Based Complement Alternat Med (2012) 0.82
The anti-inflammatory effect of Z-Ligustilide in experimental ovariectomized osteopenic rats. Inflammation (2012) 0.81
Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2010) 0.81
Living near a freeway is associated with lower bone mineral density among Mexican Americans. Osteoporos Int (2015) 0.77
Sex-related differences in the association between waist circumference and bone mineral density in a Korean population. BMC Musculoskelet Disord (2014) 0.76
Inflammation as a contributing factor among postmenopausal Saudi women with osteoporosis. Medicine (Baltimore) (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Measurement of patient outcome in arthritis. Arthritis Rheum (1980) 21.31
The diagnosis of osteoporosis. J Bone Miner Res (1994) 10.90
Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int (1998) 7.14
Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res (1997) 5.69
Clinical use of bone densitometry: scientific review. JAMA (2002) 3.73
Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res (1994) 3.29
Race and sex differences in mortality following fracture of the hip. Am J Public Health (1992) 2.63
Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med (1997) 2.50
Sex-specific and race-specific hip fracture rates. Am J Public Health (1990) 1.84
Fracture risk in the U.S. Medicare population. J Clin Epidemiol (1999) 1.49
Differences in bone mineral in young Asian and Caucasian Americans may reflect differences in bone size. J Bone Miner Res (1996) 1.34
Differences in outcome between black and white elderly hip fracture patients. J Chronic Dis (1987) 1.32
Early rheumatoid arthritis in African-Americans: the CLEAR Registry. Clin Exp Rheumatol (2004) 1.17
Sources of interracial variation in bone mineral density. J Bone Miner Res (1995) 1.01
Correlates of bone mineral density in the postmenopausal estrogen/progestin interventions trial. J Bone Miner Res (1994) 0.96
Executive summary International Society for Clinical Densitometry position development conference Denver, Colorado July 20-22, 2001. J Clin Densitom (2002) 0.95
Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am (2001) 0.94
Longitudinal bone mineral density changes in early rheumatoid arthritis. Br J Rheumatol (1994) 0.93
Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab (2002) 0.89
The antifracture efficacy of alendronate. Int J Clin Pract Suppl (1999) 0.84
A national random survey of bone mineral density reporting in the United States. J Clin Densitom (2002) 0.79
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
Years of life lost due to obesity. JAMA (2003) 12.18
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med (2006) 10.95
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (2008) 9.94
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis (2009) 4.96
Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum (2004) 4.77
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 4.67
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) (2010) 4.65
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum (2002) 4.15
Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med (2007) 4.12
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum (2012) 4.01
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 3.78
Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum (2003) 3.73
Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis (2006) 3.72
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) (2011) 3.66
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 3.64
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) (2012) 3.47
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum (2007) 3.38
REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet (2009) 3.36
Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum (2005) 3.31
Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc (2006) 2.96
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum (2010) 2.88
Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention. J Acquir Immune Defic Syndr (2012) 2.74
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum (2008) 2.61
The modified sting procedure to correct vesicoureteral reflux: improved results with submucosal implantation within the intramural ureter. J Urol (2004) 2.55
The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res (2014) 2.52
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
Measuring retention in HIV care: the elusive gold standard. J Acquir Immune Defic Syndr (2012) 2.47
Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum (2002) 2.43
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med (2007) 2.41
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol (2005) 2.40
Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 2.29
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med (2009) 2.27
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol (2008) 2.25
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med (2011) 2.17
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum (2008) 2.13
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS (2008) 2.13
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum (2010) 2.08
Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis (2006) 2.07
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) (2015) 2.03
Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis (2011) 2.02
Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf (2013) 2.01
Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study. Am J Med (2002) 2.01
Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples. Lancet (2004) 1.97
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum (2010) 1.94
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) (2013) 1.92
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab (2006) 1.88
Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum (2006) 1.85
The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol (2006) 1.82
An empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs. Am J Epidemiol (2010) 1.81
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis (2014) 1.78
Quality of care indicators for gout management. Arthritis Rheum (2004) 1.77
Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum (2004) 1.76
Randomized trial to improve fracture prevention in nursing home residents. Am J Med (2007) 1.75
Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum (2008) 1.73
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol (2005) 1.66
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf (2006) 1.65
Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest (2011) 1.63
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Validity of gout diagnoses in administrative data. Arthritis Rheum (2007) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum (2002) 1.61
Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum (2005) 1.58
The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol (2008) 1.58
The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum (2004) 1.55
Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. J Bone Miner Res (2008) 1.55
Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr (2009) 1.54
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet (2013) 1.54
Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol (2009) 1.54
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.53
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) (2012) 1.53
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther (2011) 1.53
Duration of highly active antiretroviral therapy regimens. Clin Infect Dis (2003) 1.50